MedTrace Logo

Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19

NCT04889040 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2024-01-05

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting.

Conditions

Interventions

DRUG

RO7496998

275 mg tablets

DRUG

Placebo

Matching tablets

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2021-12-02
Completion
2021-12-02

Countries

  • Argentina
  • Belgium
  • Brazil
  • Denmark
  • Germany
  • Japan
  • Mexico
  • Portugal
  • Romania
  • Switzerland
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04889040 on ClinicalTrials.gov